395 related articles for article (PubMed ID: 38014853)
61. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
62. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
63. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children.
Peters TL; Kumar V; Polikepahad S; Lin FY; Sarabia SF; Liang Y; Wang WL; Lazar AJ; Doddapaneni H; Chao H; Muzny DM; Wheeler DA; Okcu MF; Plon SE; Hicks MJ; López-Terrada D; Parsons DW; Roy A
Mod Pathol; 2015 Apr; 28(4):575-86. PubMed ID: 25360585
[TBL] [Abstract][Full Text] [Related]
64. Gene fusion detection in formalin-fixed paraffin-embedded benign fibrous histiocytomas using fluorescence in situ hybridization and RNA sequencing.
Walther C; Hofvander J; Nilsson J; Magnusson L; Domanski HA; Gisselsson D; Tayebwa J; Doyle LA; Fletcher CD; Mertens F
Lab Invest; 2015 Sep; 95(9):1071-6. PubMed ID: 26121314
[TBL] [Abstract][Full Text] [Related]
65. Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions.
Park HJ; Baek I; Cheang G; Solomon JP; Song W
J Mol Diagn; 2021 Nov; 23(11):1443-1451. PubMed ID: 34756276
[TBL] [Abstract][Full Text] [Related]
66. Development and validation of an RNA sequencing panel for gene fusions in soft tissue sarcoma.
Hu W; Yuan L; Zhang X; Ni Y; Hong D; Wang Z; Li X; Ling Y; Zhang C; Deng W; Tian M; Ding R; Song C; Li J; Zhang X
Cancer Sci; 2022 May; 113(5):1843-1854. PubMed ID: 35238118
[TBL] [Abstract][Full Text] [Related]
67. Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation.
Vargas AC; Ardakani NM; Wong DD; Maclean FM; Kattampallil J; Boyle R; Santos L; Gill AJ
Histopathology; 2021 Jun; 78(7):932-942. PubMed ID: 33128780
[TBL] [Abstract][Full Text] [Related]
68. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
[TBL] [Abstract][Full Text] [Related]
69. Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z; Xiu J; Swensen J; Vranic S
Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
[TBL] [Abstract][Full Text] [Related]
70. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
71. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
72. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
73. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
[TBL] [Abstract][Full Text] [Related]
74. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
75. NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
Kirchner M; Glade J; Lehmann U; Merkelbach-Bruse S; Hummel M; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Ploeger C; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A; Pfarr N
Genes Chromosomes Cancer; 2020 Aug; 59(8):445-453. PubMed ID: 32319699
[TBL] [Abstract][Full Text] [Related]
76. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
77. Sarcomas with sclerotic epithelioid phenotype harboring novel EWSR1-SSX1 fusions.
Antonescu CR; Rosenberg AE; Xie Z; Zhang L; Perell KA; Loya AC
Genes Chromosomes Cancer; 2021 Sep; 60(9):616-622. PubMed ID: 33987888
[TBL] [Abstract][Full Text] [Related]
78. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
79. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities.
Specht K; Sung YS; Zhang L; Richter GH; Fletcher CD; Antonescu CR
Genes Chromosomes Cancer; 2014 Jul; 53(7):622-33. PubMed ID: 24723486
[TBL] [Abstract][Full Text] [Related]
80. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
Saito M; Shimada Y; Shiraishi K; Sakamoto H; Tsuta K; Totsuka H; Chiku S; Ichikawa H; Kato M; Watanabe S; Yoshida T; Yokota J; Kohno T
Cancer Res; 2015 Jun; 75(11):2264-71. PubMed ID: 25855381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
